- Previous Close
10.18 - Open
10.00 - Bid 9.79 x 260000
- Ask 10.17 x 260000
- Day's Range
10.00 - 10.00 - 52 Week Range
9.64 - 17.33 - Volume
19 - Avg. Volume
4 - Market Cap (intraday)
809.512M - Beta (5Y Monthly) 0.84
- PE Ratio (TTM)
31.25 - EPS (TTM)
0.32 - Earnings Date Apr 24, 2025
- Forward Dividend & Yield 0.14 (1.37%)
- Ex-Dividend Date Apr 26, 2024
- 1y Target Est
--
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, and work-up products; flash systems; sample preparation products; plasmid purification solutions; oligo synthesis solutions; and metal scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables and systems; protein purification solutions, including antibody and tagged proteins purification, automation systems, and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, diagnostics, clinical, environmental protection, food safety, clinical, forensic, and academic laboratories industries. It operates in more than 80 countries, which include Americas, Europe, the Middle East, Africa, and Asia Pacific. Biotage AB (publ) was founded in 1969 and is headquartered in Uppsala, Sweden.
www.biotage.comRecent News: PQX1.F
View MorePerformance Overview: PQX1.F
Trailing total returns as of 2/28/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PQX1.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PQX1.F
View MoreValuation Measures
Market Cap
797.72M
Enterprise Value
781.27M
Trailing P/E
31.52
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.36
Price/Book (mrq)
2.18
Enterprise Value/Revenue
4.25
Enterprise Value/EBITDA
15.39
Financial Highlights
Profitability and Income Statement
Profit Margin
13.81%
Return on Assets (ttm)
4.77%
Return on Equity (ttm)
7.31%
Revenue (ttm)
2.06B
Net Income Avi to Common (ttm)
284M
Diluted EPS (ttm)
0.32
Balance Sheet and Cash Flow
Total Cash (mrq)
434M
Total Debt/Equity (mrq)
6.08%
Levered Free Cash Flow (ttm)
26M